Trial reportBlood2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 83 citations in OpenAlex.
- Trial
- ABVD plus rituximabHaematologica · 2019Trial
- Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.Pediatric blood & cancer · 2018Trial
- Glowing evidence: radiation shines in early NLPHL.Blood advances · 2026Article
- Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2026Article
- Promising outcomes of R-CHOP therapy in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: perspectives from a rare subtype.Frontiers in oncology · 2026Article
- Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.European journal of haematology · 2025Article
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment.Hematological oncology · 2025Review
- Early detection of chemotherapy-induced cardiotoxicity in lymphoma patients: RT-3DE/2D-STI and predictive role of LAEFa/LASr.American journal of cancer research · 2025Article
- Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.Frontiers in immunology · 2025Article
- Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.Haematologica · 2024Review
- Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low-middle-income country.Frontiers in oncology · 2024Article
- Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance Program.The American journal of pathology · 2024Article
- The Importance of Excisional Biopsy in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.Cureus · 2023Article
- Article
- Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2022Article
- Article
- Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.Blood advances · 2021Article
- Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up.Cancers · 2021Article
- Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients.Journal of clinical medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 3 institutions in 2 countries.
Funding
Abstract
Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. We retrospectively reviewed patients with NLPHL diagnosed between 1995 and 2015 confirmed by central pathologic review. Fifty-nine had sufficient treatment and follow-up data for analysis. We described progression-free survival (PFS), overall survival (OS), and histologic transformation according to treatment strategy and explored prognostic factors for PFS and OS. The median age at diagnosis was 41 years; 75% were male, and 61% had a typical growth pattern. Twenty-seven patients were treated with R-CHOP with an overall response rate of 100% (complete responses 89%). The median follow-up was 6.7 years, and the estimated 5- and 10-year PFS rates for patients treated with R-CHOP were 88.5% (95% confidence interval [CI], 68.4% to 96.1%) and 59.3 (95% CI, 25.3% to 89.1%), respectively. Excluding patients with histologic transformation at diagnosis, the 5-year cumulative incidence of histologic transformation was 2% (95% CI, 87% to 100%). No patient treated with R-CHOP experienced transformation. A high-risk score from the German Hodgkin Study Group was adversely prognostic for OS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.